Amsterdam, the Netherlands — October 3, 2025 — Leads & Copy — argenx SE (Euronext & Nasdaq: ARGX) will hold an Extraordinary General Meeting of shareholders at 14:00 CET on Tuesday, November 18, 2025, at the offices of Freshfields LLP (Netherlands), Strawinskylaan 10, 1077 XZ Amsterdam. Shareholders and those with meeting rights are invited to attend.
The formal notice of convocation is available on the argenx website and on www.abnamro.com/evoting. The agenda includes the adoption of a revised remuneration policy. Ancillary documents are available on the argenx website and for inspection at the argenx offices. Shareholders are encouraged to use the voting by (electronic) proxy option.
argenx is a global immunology company focused on improving the lives of people with severe autoimmune diseases. It aims to translate immunology breakthroughs into antibody-based medicines. argenx developed the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its potential in autoimmune diseases.
Contact:
Media: Ben Petok, BPetok@argenx.com
Investors: Alexandra Roy, aroy@argenx.com
Source: argenx
